Document Detail


Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission.
MedLine Citation:
PMID:  8042615     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Seven patients in second complete remission of acute myeloid leukemia (AML) aged 19-65 years were treated with polyethylene glycolated interleukin-2 (PEG IL-2), 1 x 10(6) U/M2 IV weekly as the sole postremission therapy. Second remission duration was in the range of 4-49+ months, and three patients had a second remission duration substantially longer than their first (6, 21+, and 42+ months). The results suggest that PEG IL-2 may prolong second remission duration in AML and that a prospective randomized study designed to test that idea is warranted.
Authors:
P H Wiernik; J P Dutcher; M Todd; G Caliendo; L Benson
Related Documents :
16518605 - Optimal treatment intensity in children with down syndrome and myeloid leukaemia: data ...
18784805 - Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia.
20938465 - Association of abcb1 polymorphisms with survival and in vitro cytotoxicty in de novo ac...
15975045 - Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial...
384435 - Attempts to increase the surviving length in skin flaps by a moist environment.
21982065 - Improving the clinical risk score: an analysis of molecular biomarkers in the era of mo...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  American journal of hematology     Volume:  47     ISSN:  0361-8609     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  1994 Sep 
Date Detail:
Created Date:  1994-08-19     Completed Date:  1994-08-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  41-4     Citation Subset:  IM    
Affiliation:
Albert Einstein Cancer Center/Department of Oncology, Montefiore Medical Center, Bronx, New York 10467-2490.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Female
Humans
Interleukin-2 / analogs & derivatives*,  therapeutic use,  toxicity
Leukemia, Myeloid, Acute / drug therapy*
Male
Middle Aged
Polyethylene Glycols
Chemical
Reg. No./Substance:
0/Interleukin-2; 0/Polyethylene Glycols; 0/interleukin-2, polyethylene glycol-modified

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patien...
Next Document:  Bone marrow necrosis in two patients with acute promyelocytic leukemia during treatment with all-tra...